Cyllene Therapeutics
Develops DNA medicines for severe neurogenic bladder conditions and other neurological diseases
€33MSeries C
Role not disclosedLoading investors…
Activity from announced rounds
Develops DNA medicines for severe neurogenic bladder conditions and other neurological diseases